By Business/Source
Currency:USD
2024/FY
Stock NameRevenueRatio
Business of developing and commercializing novel therapies for serious neurological and disorders4.91M100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States of America4.91M100.00%